Delving into the Latest Updates on Brise Pharmaceuticals Co., Ltd. with Synapse

Overview

Tags

Nervous System Diseases

Other Diseases

Cardiovascular Diseases

Small molecule drug

Monoclonal antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	9

Top 5 Drug Type	Count

Unknown	5
Small molecule drug	4
Monoclonal antibody	1

Top 5 Target	Count

CGRP(Calcitonin gene-related peptide)	1
TRPM3(transient receptor potential cation channel subfamily M member 3)	1
TrkA(Nerve growth factor receptor Trk-A)	1

主要研究目的：1.评估健康试验参与者单次口服[14C] BR005-036C后排泄物中的总放射性，获得人体放射性回收率数据及主要排泄途径；2.评估健康试验参与者单次口服[14C] BR005-036C后血浆、尿液和粪便的放射性代谢物谱，鉴定主要代谢产物，确定BR005-036C在人体内的生物转化途径；3.评估男性健康试验参与者单次口服[14C]BR005-036C后，全血和血浆中的总放射性，获得全血和血浆总放射性的药代动力学参数，并考察全血和血浆中总放射性的分配比。次要研究目的：1.定量分析健康试验参与者血浆中BR005-036C及其代谢产物（如适用）的药代动力学特征 2. 评估[14C]BR005-036C在健康成年试验参与者中单次口服给药的安全性

[Translation]

Primary objectives: 1. To evaluate the total radioactivity in excrement of healthy participants after a single oral dose of [14C]BR005-036C, and to obtain data on human radioactivity recovery and the main excretion pathway; 2. To evaluate the radiometabolite profiles of plasma, urine, and feces of healthy participants after a single oral dose of [14C]BR005-036C, identify the main metabolites, and determine the biotransformation pathway of BR005-036C in humans; 3. To evaluate the total radioactivity in whole blood and plasma of male healthy participants after a single oral dose of [14C]BR005-036C, obtain pharmacokinetic parameters of total radioactivity in whole blood and plasma, and investigate the partition ratio of total radioactivity in whole blood and plasma. Secondary objectives: 1. To quantitatively analyze the pharmacokinetic characteristics of BR005-036C and its metabolites (if applicable) in the plasma of healthy participants; 2. To evaluate the safety of a single oral dose of [14C]BR005-036C in healthy adult participants.

Start Date03 Mar 2026

Sponsor / Collaborator

Brise Pharmaceuticals Co., Ltd.

CTR20252402

/ CompletedPhase 1

一项评估健康受试者空腹条件下口服四种BR005-036C片剂的相对生物利用度研究

[Translation] A study to evaluate the relative bioavailability of four oral BR005-036C tablets in healthy subjects under fasting conditions

评估空腹条件下口服相同剂量的片剂B、片剂C、片剂D与片剂A相比，在健康成年受试者中的相对生物利用度

[Translation]

To evaluate the relative bioavailability of Tablets B, C, and D compared with Tablet A at the same dose in healthy adult subjects under fasting conditions

Start Date30 Jun 2025

Sponsor / Collaborator

Brise Pharmaceuticals Co., Ltd.

100 Clinical Results associated with Brise Pharmaceuticals Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Brise Pharmaceuticals Co., Ltd.

Login to view more data

100 Deals associated with Brise Pharmaceuticals Co., Ltd.

Login to view more data

100 Translational Medicine associated with Brise Pharmaceuticals Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 25 Jun 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

6

2

Preclinical

Phase 1

1

Phase 2

Other

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

BR005-036C ( CGRP )	Acute migraine More	Phase 1
Recombinant humanized anti-TrkA monoclonal antibody(Brise Pharmaceutical) ( TrkA )	Low Back Pain More	Phase 1
BR008	Neuralgia More	Preclinical
BR009	Migraine Disorders More	Preclinical
WO2025247396 Patent Mining	Arrhythmias, Cardiac More	Discovery